Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance

By Justice Department, Drug Enforcement Administration · Nov 5, 2026, 11:00 PM CST

Read full article at Federal Register
The Drug Enforcement Administration (DEA) is establishing a specific listing and DEA Controlled Substances Code Number (drug code) for 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3- chloromethcathinone; 3-CMC) in schedule I of the Controlled Substances Act (CSA). Although 3-chloromethcathinone is not specifically listed in schedule I of the CSA with its own unique drug code, it is a schedule I

Excerpt shown under fair-use limits. Full text remains with the original publisher.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

FramingThe opening frames the DEA action as a definitive regulatory step, implying authority and finality.

Technical JargonUse of specialized terminology conveys officialdom but may be opaque to lay readers.

Causal ClaimThe article links the scheduling decision directly to chemical similarity without providing supporting evidence or regulatory criteria.

Context

AI analysis

Missing context

The article does not provide context about the legal process for adding a substance to Schedule I, the criteria used by the DEA, any public comment period, the potential impact on users or researchers, or health and safety information about 3‑CMC.

Important context

Understanding that Schedule I designation carries significant legal restrictions and that positional isomer rules are part of DEA scheduling policy would help readers assess the significance of the change.

Opinion vs. reporting

AI analysis

The piece presents itself as a factual report of a regulatory action without offering analysis or opinion; however, it makes an unsupported claim about the hallucinogenic status of 4‑chloromethcathinone.